Efficacy and Safety of Neoadjuvant Luteinizing Hormone-Releasing Hormone Antagonist and Tegafur-Uracil Chemohormonal Therapy for High-Risk Prostate Cancer.
Fumiya SuginoKeita NakaneMakoto KawaseShota UedaMasayuki TomiokaYasumichi TakeuchiRisa Tomioka-InagawaToyohiro YamadaSanae NamikiNaotaka KumadaShinichi TakeuchiKota KawaseDaiki KatoManabu TakaiKoji IinumaYuki TobisawaTakuya KoiePublished in: Life (Basel, Switzerland) (2023)
This study indicates that combining neoadjuvant LHRH antagonists and UFT followed by RARP may improve oncological outcomes in patients with high-risk PCa.